Dennis Berman left the role of Director at Inhibikase Therapeutics, Inc., effective October 19, 2026. As of October 28, 2026, Inhibikase Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 20, 2026, naming 1 departure (Form 8-K, October 20, 2026).
Sell to companies like Inhibikase Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Inhibikase Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-20. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Inhibikase Therapeutics, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-20 | Out | Director | 2026-10-19 | 8-K, 2026-10-20 |
Selling to them or working with them? See who runs Inhibikase Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Inhibikase Therapeutics, Inc. and the records around it.
Inhibikase Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Sands Capital Life Sciences Pulse Fund II, L.P. also filed stake reports on 3 other companies: Acrivon Therapeutics, Inc. (Aug 2026), Alamar Biosciences, Inc. (Jul 2026), Beta Bionics, Inc. (Aug 2025)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), Faeth Therapeutics, Inc. (Aug 2026), Neurogene Inc. (Aug 2026)
Watch Inhibikase Therapeutics, Inc.
Get an email when Inhibikase Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Inhibikase Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Inhibikase Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inhibikase Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Inhibikase Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Dennis Berman, departure reported, effective 2026-10-19 (filed 2026-10-20). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Inhibikase Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Inhibikase Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Inhibikase Therapeutics, Inc.Every change, in the filing's words
Departing: Dennis Berman, Director, effective 2026-10-19
On October 19, 2026, Dennis Berman resigned from the board of directors (the "Board") of Inhibikase Therapeutics, Inc. (the "Company") and his position as Chair of the Compensation Committee of the Board (the "Compensation Committee") and a member of the Audit Committee of the Board (the "Audit Committee"), effective as of October 19, 2026.
Tools for this story
Each opens in a new tab, filled in for Inhibikase Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.